Credit Report (Nector Lifesciences Ltd)
1
CHAPTER 1 Company and its detail summarization
CHAPTER 2 Company worldwide location & subsidiaries detail
CHAPTER 3 Company cash flow and financial Status
CHAPTER 4 Aspects of international business
CHAPTER 5 Company strategies and future plans
CHAPTER 6Overall analysis and recommendations from our
side
Table of Content
2
Chapter 1
• Company and its Detail Summarization
• 1.1 Organization Business Overview
• 1.2 Company Type
• 1.3 Product Details
• 1.4 No. of Employees in Company
• 1.5 Total Revenue
• 1.6 Company Address, Contact number and Email I.d
• 1.7 Company Hierarchy of Designation
• 1.8 Company's Regulatory Certificates
• 1.9 Company’s Achievements
3
1.1 Organization Business Overview
4
Nectar Lifesciences Limited (NLL) is a pharmaceutical company in India
that founded in 1995
NLL has evolved from the manufacturer of oral and sterile range of APIs and FDFs to a composite pharmaceutical organization
Nectar Lifesciences manufactures oral & sterile active pharmaceutical ingredients, finished dosages and phytochemicals.
Nectar is the world's largest manufacturer and exporter of natural menthol and allied products.
It also manufactures empty hard gelatin capsules
The company is the largest GMP manufacturer of oral and sterile Cephalosporins in the world.
5
Nectar Lifescience is a ltd and litsted Company
Nectar Lifesciences Limited medium size pharmaceutical company
The company went public in July 2005 with simultaneous listings on Bombay Stock Exchange and the National Stock Exchange of India
The company is also in business of providing leading pharmaceutical organizations with contract research and manufacturing services.
1.2 Company Type
6
Name and Description of Product % to Total Turn Over of the Company
Drugs and Pharmaceuticals 86.80
Menthol (Phytochemical) 11.35
Diagnostics Kits 1.85
*In March 2011, the company received approval from
the Japanese MOH for their product, Cefuroxime
Axetil.
1.3 Product Details
7
Nectar family consists of over 2000 members
Revenue
1663.4
INR Cr.
Net Profit
66.26
INR Cr.
1.4 No. of Employees in Company
1.5 Total Revenue (FY-14-15)
8
Nectar Lifesciences Ltd
SCO 38-39, Sector 9d,
Chandigarh 160009,
India
Ph:+91172-3047777
Fax:+91172-3047755
Nectar Lifesciences Ltd
D-708, Crystal plaza,
Off New link Road,
Opp Infinitti Mall, Andheri (W),
Mumbai-400053
Ph:+9122-32060171
Fax:+9122-26736793
1.6 Company Address, Contact Number
Mrs. Rima Marphatia
(Non Executive Director)
Mr. Sanjive Goyal
(Chairman &Managing Director)
Mr. Dinesh Dua
(Chief Executive Officer and Director)
Mr. Raman Kapoor
(Director)
Dr. (Maj. Gen) S. S. Chauhan
(Director)
Mr. HarPrakash Gill
(Non Promoter Executive Director)
Mr. Ajay Swaroop
(Director)
Mr. Neera Singh
(Additional Director)
Mr. Vijay Shah
(Director)
Mr. Vivek Shett
(Director)
9
1.7 Company Management
ANVISA GMP approval received for formulation facility
In March 2011, the company received approval from the Japanese MOH for their product,
Cefuroxime Axetil.
CEP received for Cefotaxime sodium Sterile
NecLife has filed 44 Drug Master Files (DMFs) in highly regulated markets and 15
Abbreviated New Drug Applications (ANDAs). The company expects to file another 20
DMFs and 10 ANDAs/EU Dossiers from Dera Bassi and Baddi facilities in this fiscal year.
February 2012: Japanese PMDA approval received for
active pharmaceutical ingredients manufacturing
facility.
December 2011: European GMP approval received for
finished formulations manufacturing facility.
October 2011: European GMP approval received for active pharmaceutical ingredients
manufacturing facility.
September 2011: US Food and Drug Administration's approval received for active pharmaceutical ingredients
manufacturing facility.
Certification
10http://www.fortshare.net/CompanyProfile/ManagementDiscussion.aspx?id=83&FinCode=132649
1.8 Regulatory Certification
11
1.9 Achievements
Nectar wins "Outstanding Exports Award, 2014-15" by Pharmexcil.
Nectar awarded with the National Energy Conservation award by Beaureu
of Energy Efficiency, Ministry of Power, Govt of India
Nectar honored as the fastest growing pharmaceutical company by CNBC
TV 18 and State Bank of India
Nectar's Chairman Mr Sanjiv Goyal wins "Outstanding Entrepeneurship
Award -2014" by APEA
Nectar breaks into Fortune 500 India, ranking 19th in Indian Pharma
Chapter 2
• 2.1 Company’s Subsidiaries and Plant Location
12
13
Subsidiaries Name Address Country
Nectar lifescience UK limited Devonshire House
60 Goswell Road
London
United kingdom
M/S Chem pharma pvt. ltd. Wagawatta Road,
Horana
Sri Lanka
Sri Lanka
Nectar lifescience USA LLC USA
Type of Products Being
Manufactured
Address State
Formulation Unit and Empty Hard
Gelatin Capsule Unit (2 plants)
Unit III & IV : Village Bhatoli Kalan,
Pargana Dharampur, Tehsil Nalagarh
Solan District
Himachal Pradesh
API and Menthol Plant (8 plants) Vill:Saidapura,
Tehsil:Dehrabasti,
Patiala
Punjab
Menthol Plant (1 Plant) Narbada Industries Plot No. 2, Lane No.
4, Phase II, SIDCO Industrial Complex,
Bari Brahmana
Jammu
Jammu & Kashmir
Plants
Subsidiaries
2.1 Company’s Subsidiaries and Plant Location
Chapter 3
• Company Cash Flow and Financial Status
• 3.1 Balance Sheet
• 3.2 Profit and Loss Statement
• 3.3 Share Holders
• 3.4 Debt Clearance Management
14
15
0
500
1000
1500
2000
2500
3000
1091.441336.38
1406.44 1467.011552.52
1812.62
2120.93
2274.042394.07
2510.47
Liabilities Assets
2011 2012 2013 2014 2015
*Liabilities are increasing at faster rate than Assets
3.1 Balance sheet ( In INR Cr. )
Year
INR
Cr.
16
0
200
400
600
800
1000
1200
1400
1600
1800
1075.52
1326
1042.29
1649.94 1663.64
103.92 73.25 85.67 62.08 66.26
Revenue Profit/Loss After Tax
2011 2012 2013 2014 2015
*Total Revenue has increased, However the profit has been decreasing over a
period of Five year
3.2 Profit & Loss (In INR. Cr.)IN
R C
r.
Year
17
3.3 Share Holders
*Foreign and institutional share holding are less ,which is not a positive sign of the company
0
100
200
300
400
500
600
700
800
900
1000
564.35
928.83
770.07803.18
860.83
103.92 73.25 85.6762.08
66.26
Total Borrowing Profit/Loss After Tax
20152012 2013 20142011
* Total borrowings are increasing at faster rate than profit, No such long term benefits are clearly
visible18
3.4 Debt Clearance Management (In Rs. Cr.)IN
R C
r.
Year
Chapter 4
• Aspects of International Business
• 4.1 Recent one year Export Details
• 4.2 Recent One Year Import Details
• 4.3 Comparison of Revenue Generated from Export
19
Export Items Fall in Following Chapters
4.1 Recent One Year Export Details
Chapter 13
1 Product
Chapter 29
27 Products
Chapter 30
1 Product
Chapter 33
5 Products
Chapter 35
1 Products
Chapter 38
1 Products
Chapter 39
1 Product
20
*NLL exporting products in 82 Countries
Some Of Countries are Given Blow
United States Afghanistan Iraq Saudi Arabia
Japan Argentina Kenya Spain
Egypt Brazil Mexico Switzerland
France Russia Netherlands United Kingdom
21
4.3 Comparison of Revenue Generated from Export
940
960
980
1000
1020
1040
1060
1080
1100
1120
1140
1013
1126
Re
ve
nu
e (
INR
Cr.
)
Year
2015 2016
Chapter 28
2 Product
Chapter 29
22 Products
Chapter 30
3 Product
Chapter 35
1 Products
Chapter 38
2 Products
Chapter 39
1 Products
Chapter 84
1 Product
Chapter 90
8 Product
4.2 Recent One Year Import Details
Import Items Fall in Following Chapters
22
Some Of Countries are Given Blow
Austria United Kingdom Spain Italy
Belgium United States France South African Republic
*NLL importing products from 18 Countries
23
Chapter 5
• 5.1 Company’s Strategies and Future plans
24
5.1 Company’s Strategies and Future plans
Chapter 6
• Overall Analysis and Recommendations from Our Side
25
NSR-backed Nectar Life set to defend winding up suit
The legal tussle between Indian drug makers -- Hetero Drugs and Nectar Lifesciences -- is
moving to the next level as the Punjab and Haryana High Court will hear the winding up
petition filed against Nectar Lifesciences by Hetero Drugs on Thursday.
Earlier, the court had issued a show-cause notice against Punjab-based Nectar Lifesciences
Ltd asking the company why a winding up petition, filed by Hyderabad-based Hetero
Drugs Ltd, should not be admitted against Nectar for alleged default of the long
outstanding dues of Rs 3.2 crore which Nectar is indebted to Hetero Drugs.
26
5.1 Company’s Offence
5.2 Company’s Rating
Nectar Lifesciences
5.8/10 C++
27
Points Obtain Grade Recommendation
10 A++ Highest degree of safety
9 A+ Highest degree of safety
8 B++ High degree of safety
7 B+ High degree of safety
6 C++ Adequate degree of safety
5 C+ Adequate degree of safety
4 D++ Moderate risk
3 D+ Moderate risk
2 E++ Highest Risk
1 E+ Highest Risk
Modifier "+" (plus) / "-"(minus) reflect the comparison within the category.
Rating Methodology
Lifescience Intellipedia Pvt. Ltd.
Suite no- 101, C- 104, Sector- 65 Noida UP- 201301
Contact No- 0120 6900 550-565
Email address- [email protected]
28
Nothing will improve your credit score faster than paying down debt
Top Related